Table 3.
Outcome parameters of MPCNL and RIRS
| Study | Treatments | SFR(%) | Hospitalization time(day) | Operation | Postoperative | Hb drop(g/dl) | Transfusion,n(%) | cost | Complications(%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| duration(min) | pain score | Overall n(%) | Grade I n(%) | Grade II n(%) | Grade III n(%) | |||||||
| Gu 2013 [25] | mPCNL | 100 | 4.6 ± 1.8 | 50–135(96.2) | - | - | - | - | - | - | - | - |
| RIRS | 89.7 | 1.9 ± 1.3 | 45–100(66.8) | - | - | - | - | - | - | - | - | |
| Sabnis 2013 [26] | mPCNL | 97.1 | 2.4 ± 0.9 | 51.6 ± 18.5 | 1.9 ± 1.2 | 0.96 ± 0.41 | - | - | 9(25.7) | 8(22.9) | 1(2.8) | 0 |
| RIRS | 94.3 | 2.1 ± 0.75 | 47.1 ± 17.5 | 1.6 ± 0.8 | 0.56 ± 0.31 | - | - | 4(11.4) | 4(11.4) | 0 | 0 | |
| Kumar 2015 [27] | mPCNL | 95.1 | 3.1 | 61.1 ± 1.3 | - | - | 12.9 | - | 10(24.9) | 8(20) | 2(4.9) | - |
| RIRS | 86.1 | 1.3 | 47.5 ± 1.1 | - | - | 0 | - | 4(9.4) | 2(4.7) | 2(4.7) | - | |
| Lee 2015 [28] | mPCNL | 85.7 | 1.6 ± 1.1 | 76.1 ± 70.6 | 4.2 ± 2.6 | 0.69 ± 0.98 | - | - | 15(42.9) | 11(31.4) | 4(11.4) | 0 |
| RIRS | 97 | 1.5 ± 0.9 | 99.6 ± 60.8 | 5.7 ± 3.0 | 0.38 ± 0.97 | - | - | 22(62.9) | 19(54.3) | 3(9.1) | 0 | |
| Demirbas 2016 [29] | mPCNL | 80 | 2.46 ± 3.02 | 54.53 ± 23.09 | 4.73 ± 1.25 | - | - | 665 | 7(23.4) | 2(6.7)a | 5(16.7) | |
| RIRS | 74.4 | 1.37 ± 1.48 | 59.41 ± 15.78 | 2.30 ± 1.12 | - | - | 1160 | 6(14) | 3(7)a | 3(7) | ||
| Fayad 2017 [30] | mPCNL | 92.72 | 71.66 ± 10.36 | - | 0.28 | 0 | - | 5(8.33) | 5(8.33) | - | - | |
| RIRS | 84.31 | 109.66 ± 20.75 | - | 0.13 | 0 | - | 5(8.33) | 5(8.33) | - | - | ||
| Kandemir 2017 [31] | mPCNL | 93.7 | 54.2 | 59.04 | - | 1.06(0.1–28) | 3.3 | - | 5(16.6) | 4(13.3) | 1(3.3) | 0 |
| RIRS | 86.7 | 19 | 51.05 | - | 0.75(0.1–21) | 0 | - | 6(19.9) | 4(13.3) | 2(6.6) | 0 | |
| Zeng 2018 [32] | mPCNL | 93.8 | 2.5 ± 1.1 | 58.6 ± 21.6 | 2.7 ± 1.7 | 1.02 ± 0.89 | 0 | - | 6(7) | 9(11.7) | 2(2.6) | - |
| RIRS | 82.5 | 2.5 ± 1.1 | 52.3 ± 22.4 | 2.0 ± 1.5 | 0.43 ± 0.88 | 0 | - | 6(7) | 12(14.5) | 2(2.6) | - | |
| Gucuk 2019 [33] | mPCNL | 86.7 | 2.1 ± 2.03 | 98.3 ± 18.8 | 3.1 ± 1.4 | - | 3.3 | - | 12(40) | 9(30) | 3(10) | 0 |
| RIRS | 83.3 | 1.6 ± 1.34 | 109.0 ± 33.8 | 3.0 ± 1.4 | - | 0 | - | 9(30) | 6(20) | 1(3.3) | 2(6.6) | |
| Jiang 2019 [17] | mPCNL | 94.7 | 3.2 ± 0.5 | 54.0 ± 8.2 | - | 3.0 ± 2.3 | - | - | 4(6.9) | 3(5.2) | 1(1.7) | 0 |
| RIRS | 92.9 | 3.2 ± 0.6 | 60.3 ± 8.5 | - | 2.3 ± 1.5 | - | - | 6(5.2) | 0 | 4(3.4) | 2(1.7) | |
| Jin 2019 [18] | mPCNL | 99.1 | 5.59 ± 0.82 | 79.6 ± 14.86 | 3.42 ± 1.24 | 1.14 ± 0.76 | - | - | 12(11) | 0 | 12(11) | 0 |
| RIRS | 97.3 | 3.15 ± 0.72 | 87.2 ± 13.34 | 1.62 ± 0.86 | 0.98 ± 0.68 | - | - | 6(5.5) | 0 | 6(5.5) | 0 | |
| Zhang 2019 [19] | mPCNL | 98 | 5.3 ± 1.2 | 68.58 ± 15.82 | - | 0.89 | 1.6 | 4085.51 ± 416.69 | 10(16.7) | 2(3.3) | 5(8.3) | 3(5) |
| RIRS | 92 | 3.2 ± 0.5 | 93.35 ± 21.64 | - | 0.44 | 0 | 4657.28 ± 679.28 | 6(10) | 2(3.3) | 3(5) | 1(1.7) | |
| Yavuz 2020 [34] | mPCNL | 94.1 | 2 (1–14) | 61.6 ± 18.5 | - | - | - | 632 ± 314 | 3(8.8) | - | 3(8.8) | 0 |
| RIRS | 76 | 1 (0.5-3) | 60.7 ± 13 | - | - | - | 1250 ± 505 | 2(6) | - | 2(6) | 0 | |
| Coskun 2021 [35] | mPCNL | 4.6 ± 3,5 | 71.7 ± 24.4 | - | - | 8 | - | - | 7(28) | 9(36) | 9(36) | |
| RIRS | 1.2 ± 0.59 | 72.8 ± 24.2 | - | - | 0 | - | - | 20(78) | 3(12) | 0 | ||
| Jain 2021 [36] | mPCNL | 92.5 | 2.85 | 51.58 | - | 0.88 | - | - | 9(22.5) | 2(5) | 3(7.5) | 4(10) |
| RIRS | 87.5 | 2.45 | 69.75 | - | 0.42 | - | - | 16(40) | 4(10) | 7(17.5) | 5(12.5) | |
| Datta 2022 [20] | mPCNL | 100 | 39.21 | 41.17 | - | 0.46 | - | 45.61 | 10(10.3) | 6(6.2) | 4(4.1) | 0 |
| RIRS | 73 | 39.08 | 73.58 | - | 0.31 | - | 423.02 | 16(35) | 16(35) | 0 | 0 | |
| Liu 2022 [21] | mPCNL | 86.2 | 3.5 ± 1.58 | 48.2 ± 24.25 | 4.6 ± 1.34 | 0.98 ± 0.55 | 5.2 | - | 13(22.4) | 13(22.4) | - | - |
| RIRS | 61.4 | 2.5 ± 1.24 | 43.5 ± 17.23 | 3.9 ± 1.07 | 0.76 ± 0.58 | 0 | - | 4(7) | 4(7) | - | - | |
| Sebaey 2022 [37] | mPCNL | 88.6 | 1.41 ± 0.46 | 59.71 ± 19.44 | - | 1.27 ± 0.1 | 2.9 | - | 3(8.6) | 3(8.6) | - | - |
| RIRS | 82.9 | 1.29 ± 0.44 | 80.43 ± 14.79 | - | 1.29 ± 0.1 | 0 | - | 1(2.9) | 1(2.9) | - | - | |
aoverall number of Grade I and Grade II; mPCNL minimally invasive percutaneous nephrolithotomy, RIRS Retrograde intrarenal surgery, Hb Hemoglobin, SFR Stone free rate